Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.
Authors
- Karen Samaan (ORCID: https://orcid.org/0000-0003-2780-9232)
- Anil Gaur (ORCID: https://orcid.org/0000-0002-8346-6652)
- Ravneet Arora
- Kris Todd
- R Moses
- D Clemow
- Bruce E Sands
- Axel Dignass
- Peter M Irving
- Laurent Peyrin-Biroulet
- Geert D’Haens
Institutions
- Eli Lilly (United States) (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- McGill University Health Centre (CA)
- Agaplesion Markus Hospital (DE)
- Amsterdam University Medical Centers (NL)
- Kitasato Institute Hospital (JP)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- Université de Lorraine (FR)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1093/ibd/izag007
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 30.93